{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-064754","form_type":"8-K","ticker":"NNVC","cik":"0001379006","company_name":"NANOVIRICIDES, INC.","filed_at":"2026-05-21T10:01:46+00:00","discovered_at":"2026-05-21T10:05:01.200297+00:00","generated_at":"2026-05-21T10:09:21.793817+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"NanoViricides says NV-387 and NV-387-remdesivir expected to be effective against Ebola Bundibugyo strain in DRC","bullets":["NV-387 is broad-spectrum antiviral entering Phase II for Mpox in DRC.","NV-387-remdesivir is an oral formulation shown in animal models; PLOS ONE paper published.","Encapsulation protects remdesivir from metabolism, improving efficacy per company.","Company has a clinical site in DRC for Mpox; public health responders to decide on Ebola.","Remdesivir was tested in prior Ebola trials but efficacy not established; antibodies approved only for Zaire strain."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-064754","json":"https://secwatch.observer/filing/0001104659-26-064754.json","markdown":"https://secwatch.observer/filing/0001104659-26-064754.md","text":"https://secwatch.observer/filing/0001104659-26-064754.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1379006/000110465926064754/0001104659-26-064754-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1379006/000110465926064754/tm2615268d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T10:09:21.793817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}